List of Excipients in Branded Drug ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE

Generic Drugs Containing ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE

Company	Ingredient	NDC	Excipient
LUPIN LIMITED	abacavir sulfate, lamivudine and zidovudine	57297-286	CELLULOSE, MICROCRYSTALLINE
LUPIN LIMITED	abacavir sulfate, lamivudine and zidovudine	57297-286	CROSPOVIDONE
LUPIN LIMITED	abacavir sulfate, lamivudine and zidovudine	57297-286	FD&C BLUE NO. 2
LUPIN LIMITED	abacavir sulfate, lamivudine and zidovudine	57297-286	FERRIC OXIDE YELLOW

What are the Most Frequently-Used Excipients in ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	CROSPOVIDONE
1	FD&C BLUE NO. 2
1	FERRIC OXIDE YELLOW

Abacavir Sulfate, Lamivudine and Zidovudine Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

The abacavir sulfate/lamivudine/zidovudine fixed-dose combination is an established triple-nucleoside reverse transcriptase inhibitor tablet marketed in the United States as Trizivir. Its core commercial opportunity is no longer premium originator pricing. It is cost-efficient generic manufacture, supply of validated excipient systems, lifecycle reformulation for underserved markets, and contract manufacturing for jurisdictions where legacy antiretroviral regimens remain clinically relevant.

The principal formulation challenge is combining three high-dose active ingredients in a single immediate-release tablet while controlling tablet weight, compression behavior, dissolution, chemical stability, and manufacturing cost. The commercial ceiling is limited by generic competition and the migration of HIV treatment toward dolutegravir-based regimens.

What is the formulation of abacavir sulfate, lamivudine and zidovudine?

The product contains 300 mg of abacavir, supplied as abacavir sulfate, 150 mg of lamivudine, and 300 mg of zidovudine per tablet. The total active drug load is approximately 750 mg before accounting for the sulfate counterion and excipients.[1]

The U.S. product is an immediate-release, film-coated tablet. The inactive ingredients identified in the U.S. labeling include:

Formulation component	Function
Microcrystalline cellulose	Diluent and compression aid
Sodium starch glycolate	Superdisintegrant
Colloidal silicon dioxide	Glidant and flow aid
Magnesium stearate	Lubricant
Hypromellose	Film-forming polymer
Titanium dioxide	Opacifier and colorant
Triacetin	Plasticizer

The exact commercial opportunity depends on the target jurisdiction and dosage form. A generic manufacturer can generally select alternative compendial excipients, but the finished product must meet applicable quality, bioequivalence, dissolution, stability, and manufacturing requirements.

What excipient properties matter most?

The formulation has a high active-to-excipient ratio. This creates four technical priorities:

1. Powder flow: The active ingredients must feed consistently into the die, particularly at commercial production speeds.
2. Content uniformity: A small-dose component such as lamivudine must distribute evenly alongside two larger drug loads.
3. Disintegration and dissolution: Excessive lubricant or inadequate disintegrant performance can delay release.
4. Moisture control: Water activity and packaging affect tablet hardness, dissolution, chemical stability, and film-coat performance.

Microcrystalline cellulose is commercially attractive because it supports direct compression and can reduce process complexity. A co-processed excipient system based on microcrystalline cellulose and a high-functionality disintegrant may improve flow and tablet robustness, but it can increase excipient cost and require additional formulation development.

What excipient strategies are available for generic manufacturers?

Direct-compression strategy

Direct compression is the lowest-complexity route if the three active ingredients have acceptable flow, compressibility, and segregation behavior. It minimizes unit operations and can reduce capital expenditure, solvent use, drying time, and validation burden.

The principal risks are:

• segregation during blending or transfer;
• poor die filling at high speed;
• tablet capping or lamination;
• variability in hardness and friability;
• dissolution changes caused by lubricant overmixing.

A generic developer should evaluate particle-size distribution, bulk density, tapped density, shear-cell flow, electrostatic behavior, and segregation propensity for each active ingredient and excipient grade.

Wet-granulation strategy

Wet granulation can improve flow and content uniformity when direct compression is unstable. It is more expensive and introduces water exposure, drying requirements, and possible degradation or polymorphic changes.

A selective granulation approach may be preferable to granulating all three active ingredients together. For example, a formulation developer could granulate the poorly flowing fraction while retaining a free-flowing component for final blending. This may improve manufacturability without adding excessive tablet mass.

The main commercial drawback is process complexity. Wet granulation also increases the number of critical process parameters that must be controlled in an abbreviated new drug application.

Roller-compaction strategy

Dry granulation by roller compaction can provide a middle path between direct compression and wet granulation. It avoids water and can improve flow and density. It may be useful where moisture sensitivity, limited drying capacity, or high-volume production favors a dry process.

The formulation risks include over-compaction, reduced tabletability after milling, and slower dissolution. The process requires control of ribbon density, milling conditions, particle-size distribution, and lubricant blending.

Film-coating strategy

The film coat is primarily a product-identification, swallowability, appearance, and handling layer. It also provides limited protection against abrasion and environmental exposure.

Commercially, a generic manufacturer can reduce cost through:

• lower coating weight;
• efficient aqueous coating systems;
• standard white or colored film-coat platforms;
• optimized spray rate and inlet-air conditions;
• reduced batch cycle time.

A distinctive color or shape may create trade-dress considerations, but those considerations do not replace an assessment of trademark and unfair-competition risk.

What commercial opportunities exist for excipient suppliers?

The strongest opportunity is not a proprietary excipient claim directed specifically to the triple combination. It is a validated formulation platform that addresses the process risks of high-dose fixed-dose antiretroviral tablets.

High-functionality excipient systems

Suppliers can position:

• directly compressible microcrystalline cellulose;
• co-processed cellulose-based excipients;
• low-moisture grades;
• high-efficiency crospovidone or sodium starch glycolate;
• lubricant systems designed to reduce dissolution impact;
• low-peroxide excipients where oxidative degradation is a concern.

A supplier that provides formulation support, scale-up data, and regulatory documentation has a stronger commercial position than one selling a commodity grade alone.

Packaging-linked excipient strategy

Packaging can be part of the formulation strategy. High-density polyethylene bottles with desiccants may reduce moisture exposure and support longer shelf life. Blister packaging may improve dose administration and adherence but can raise packaging cost.

An excipient supplier can create value by linking excipient grade selection to:

• water activity;
• tablet hardness;
• dissolution after accelerated aging;
• extractables and leachables;
• stability in tropical climates;
• bottle versus blister packaging.

Contract development and manufacturing

Contract development organizations can offer a package covering formulation, analytical method development, pilot manufacture, stability studies, and commercial scale-up. This is particularly relevant for regional generic manufacturers that lack internal fixed-dose combination expertise.

The target customers include:

• generic antiretroviral manufacturers;
• public-sector procurement suppliers;
• global-health procurement contractors;
• manufacturers supplying sub-Saharan African and South Asian markets;
• companies seeking additional approved sources for active pharmaceutical ingredients and finished tablets.

When does abacavir, lamivudine and zidovudine lose exclusivity?

The principal United States product, Trizivir, was approved by the FDA in 2000 under NDA 021752.[1] The original active-ingredient and combination-product patent positions are historical rather than current commercial barriers in the United States. Generic versions have been available, and the product is listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book.[2]

Exclusivity or protection category	Current commercial assessment
New chemical entity exclusivity	Expired
Originator regulatory exclusivity	Expired
Core active-ingredient patents	Expired or commercially nonblocking in the United States
Combination-product patent protection	Historical; requires jurisdiction-specific review
Formulation patents	No broad current barrier established from the standard U.S. product label
Biosimilar exclusivity	Not applicable
Generic pathway	ANDA, subject to applicable FDA requirements

Exact patent expiration analysis must be performed by jurisdiction and patent family. Patent term adjustment, terminal disclaimers, pediatric extensions, national-phase differences, and supplementary protection certificates can produce different outcomes outside the United States.

What is the Orange Book status of Trizivir and its generic equivalents?

The FDA Orange Book identifies approved products, dosage forms, strengths, therapeutic-equivalence evaluations, and patent or exclusivity information where applicable.[2] Trizivir is an immediate-release oral tablet containing the three active ingredients.

For a generic applicant, the relevant regulatory route is generally an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must demonstrate pharmaceutical equivalence and bioequivalence and must address listed patents and exclusivities through the applicable certification pathway.

Are Paragraph IV challenges relevant?

Paragraph IV certifications remain legally relevant when an applicant asserts that a listed patent is invalid, unenforceable, or not infringed. For an old combination product with expired core protection, the principal risks are less likely to be a new Paragraph IV campaign and more likely to involve:

• jurisdiction-specific patent remnants;
• manufacturing-process patents;
• formulation patents;
• regulatory exclusivity differences;
• patent listings associated with a particular product or indication.

A Paragraph IV strategy should be based on the current Orange Book listing, not on historical patents identified in secondary databases.

What patents protect the formulation?

The commercial formulation should be analyzed across five patent categories:

1. Active ingredients: Patents covering abacavir, lamivudine, or zidovudine as chemical entities.
2. Combination therapy: Claims covering the use or composition of all three active ingredients.
3. Dosage form: Claims covering a tablet, fixed-dose ratio, release profile, or particular excipient combination.
4. Method of treatment: Claims directed to treating HIV infection using the combination.
5. Manufacturing process: Claims covering granulation, compression, coating, or impurity control.

For a conventional immediate-release tablet using common excipients, the probability of a broad, durable formulation barrier is lower than for a modified-release, long-acting, injectable, or device-based product. The most defensible new intellectual property would usually require a measurable technical effect, such as improved stability, reduced impurity formation, enhanced dissolution under discriminatory conditions, or a materially improved manufacturing process.

A patent directed only to substituting one conventional diluent for another may face enablement, obviousness, and lack-of-technical-effect challenges.

How strong is the patent estate for abacavir sulfate, lamivudine and zidovudine?

The patent estate is commercially weak for the conventional U.S. immediate-release product because:

• the product was approved more than two decades ago;
• the active ingredients are established antiretrovirals;
• generic competition exists;
• the formulation uses conventional excipients;
• the major clinical market has shifted toward integrase inhibitor-based treatment.

Patent strength can still be higher in selected markets if a local patent covers a specific combination, process, or formulation. A global freedom-to-operate review should map national filings, granted claims, legal status, and claim scope rather than rely on the U.S. position.

What generic entry risks exist?

Generic launch risk is mainly commercial and regulatory rather than originator patent-driven.

Risk	Business effect	Mitigation
Low price ceiling	Limits return on formulation investment	Use low-cost process and shared manufacturing assets
High tablet weight	Raises swallowing and packaging concerns	Optimize density and compression
Content-uniformity failures	Can delay approval or scale-up	Use segregation studies and robust blending controls
Dissolution variability	Creates bioequivalence risk	Establish discriminatory dissolution methods early
Tropical stability	Can shorten shelf life	Select low-moisture excipients and protective packaging
Declining clinical demand	Reduces forecast volume	Target institutional and legacy-regimen markets
Procurement concentration	Increases price pressure	Obtain multiple market authorizations
Abacavir safety screening	Limits use in some patients	Support labeling and HLA-B*5701 screening requirements

The product also carries clinical limitations. Abacavir requires consideration of hypersensitivity risk and HLA-B*5701 status, and current treatment guidelines often favor dolutegravir-based combinations over older triple-nucleoside regimens.[3,4]

How does this product compare with newer HIV fixed-dose combinations?

Product class	Typical active-drug strategy	Market position
Abacavir/lamivudine/zidovudine	Three nucleoside reverse transcriptase inhibitors	Legacy regimen; generic and price-driven
Abacavir/lamivudine	Two-nucleoside backbone	Still used in selected settings, often with an integrase inhibitor
Tenofovir/lamivudine/dolutegravir	Two nucleoside analogues plus integrase inhibitor	Stronger current public-health and commercial position
Bictegravir/tenofovir alafenamide/emtricitabine	Integrase inhibitor-based single-tablet regimen	Branded and higher-value segment
Long-acting injectable regimens	Injectable integrase inhibitor and reverse transcriptase inhibitor	Differentiated, higher technical and patent barriers

The triple-nucleoside product can compete on established manufacturing, low ingredient cost, and procurement familiarity. It is poorly positioned to compete on modern guideline preference, resistance profile, convenience, or premium pricing.

What licensing and partnership opportunities exist?

Direct licensing of the legacy product is likely to be less attractive than regional commercialization and technology-transfer arrangements. Potential structures include:

• nonexclusive licenses for local manufacture;
• technology-transfer agreements for direct compression or dry granulation;
• supply agreements for qualified excipient grades;
• dual-source arrangements with public-health procurement suppliers;
• regional rights for countries where the product remains listed in treatment programs;
• contract packaging for government tenders.

No material current licensing transaction should be assumed without review of the relevant company filings, product agreements, and territory-specific registrations. Originator revenue for this combination is generally not disclosed as a standalone product metric, so revenue exposure should be modeled from tender data, shipment volumes, market authorization records, and generic pricing rather than from a separately reported brand forecast.

What FDA regulatory status and manufacturing barriers apply?

FDA approval of the reference product establishes the regulatory identity of the combination, but each generic applicant must independently demonstrate compliance with current requirements. Key development work includes:

• analytical method validation for all three active ingredients;
• impurity and degradation-product control;
• comparative dissolution;
• assay and content uniformity;
• tablet hardness, friability, and disintegration;
• accelerated and long-term stability;
• container-closure qualification;
• bioequivalence support;
• process validation and continued process verification.

The highest manufacturing barrier is usually not the excipient itself. It is maintaining uniformity and dissolution at scale while keeping the tablet compact, mechanically robust, and inexpensive.

Key Takeaways

• The product is a legacy immediate-release fixed-dose tablet containing abacavir sulfate, lamivudine, and zidovudine.
• Its labeled excipient system uses conventional diluent, disintegrant, glidant, lubricant, and film-coat components.[1]
• The best excipient opportunity is a validated high-dose direct-compression or dry-granulation platform, not a commodity substitution claim.
• U.S. originator exclusivity and core patent barriers are historical; generic entry is established through the ANDA pathway.
• Biosimilar risk does not apply because the product is a small-molecule tablet.
• Commercial demand is constrained by the shift toward dolutegravir-based HIV regimens.
• Regional generic supply, public-sector tenders, technology transfer, and excipient-plus-development packages are the most credible opportunities.
• Any new formulation patent should rely on measurable stability, dissolution, impurity, or manufacturing advantages.

FAQs

Can a new excipient combination receive patent protection?

Yes, but conventional excipient substitution alone is unlikely to provide strong protection. A stronger case requires a reproducible technical effect tied to a defined composition or process.

Is abacavir sulfate compatible with direct compression?

It can be used in a direct-compression design, but compatibility depends on particle properties, moisture, flow, compressibility, and interaction with lamivudine and zidovudine. Scale-up data are essential.

Does the product require a biosimilar application?

No. Abacavir sulfate, lamivudine, and zidovudine are small-molecule active ingredients. A generic applicant generally uses the ANDA pathway rather than the biosimilar pathway.

Is a pediatric liquid formulation a major opportunity?

It is a possible lifecycle strategy, but it creates additional taste-masking, preservative, chemical-stability, dosing-accuracy, and pediatric-bioequivalence challenges. The commercial opportunity depends on local treatment guidelines and procurement demand.

Which packaging format is commercially preferable?

High-density polyethylene bottles with desiccant systems usually favor low-cost bulk distribution. Unit-dose blister packaging may improve adherence, traceability, and institutional dispensing but typically increases packaging cost.

References

1. U.S. Food and Drug Administration. (2000). Trizivir (abacavir sulfate, lamivudine, and zidovudine) tablets: Prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
3. U.S. Department of Health and Human Services. (2024). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. National Institutes of Health.
4. World Health Organization. (2021). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: Recommendations for a public health approach. WHO.
5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.